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Purpose: We previously deﬁned biallelic HYAL2 variants causing a novel disorder in 2 families,
involving orofacial clefting, facial dysmorphism, congenital heart disease, and ocular abnormalities, with Hyal2 knockout mice displaying similar phenotypes. In this study, we better
deﬁne the phenotype and pathologic disease mechanism.
Methods: Clinical and genomic investigations were undertaken alongside molecular studies,
including immunoblotting and immunoﬂuorescence analyses of variant/wild-type human
HYAL2 expressed in mouse ﬁbroblasts, and in silico modeling of putative pathogenic variants.
Results: Ten newly identiﬁed individuals with this condition were investigated, and they were
associated with 9 novel pathogenic variants. Clinical studies deﬁned genotype–phenotype
correlations and conﬁrmed a recognizable craniofacial phenotype in addition to myopia, cleft
lip/palate, and congenital cardiac anomalies as the most consistent manifestations of the
condition. In silico modeling of missense variants identiﬁed likely deleterious effects on
protein folding. Consistent with this, functional studies indicated that these variants cause
protein instability and a concomitant cell surface absence of HYAL2 protein.
Conclusion: These studies conﬁrm an association between HYAL2 alterations and syndromic
cleft lip/palate, provide experimental evidence for the pathogenicity of missense alleles, enable
further insights into the pathomolecular basis of the disease, and delineate the core and variable
clinical outcomes of the condition.
© 2021 The Authors. Published by Elsevier Inc. on behalf of American College of Medical
Genetics and Genomics. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Introduction
We ﬁrst identiﬁed abnormalities in HYAL2 function
through studies of a novel syndromic form of orofacial

clefting in 5 Amish and 2 Saudi Arabian individuals1
associated with 2 distinct homozygous HYAL2 missense
variants. Affected individuals displayed a remarkably
consistent pattern of craniofacial dysmorphism involving
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bilateral/unilateral cleft lip and palate, penetrant in all but 1
Saudi Arabian child, along with more variable features,
including congenital cardiac anomalies (cor triatriatum
sinister), myopia with staphyloma, cataract, conductive/
sensorineural hearing loss, pectus excavatum, and single
palmar creases. Consistent with the human condition,
Hyal2–/– mice displayed similar craniofacial abnormalities
with submucosal cleft palate, and in a proportion of mice,
cor triatriatum sinister and hearing loss were identiﬁed.1 To
date, no further affected individuals have been described.
HYAL2 is a cell-surface protein proposed to act as a
hyaluronidase enzyme in concert with HYAL1, the other
major mammalian hyaluronidase acting in somatic tissues,
catalyzing the degradation of the high molecular weight
glycosaminoglycan polymer hyaluronan.2,3 Hyaluronan, a
core constituent of the extracellular matrix, plays key roles
in early development by providing the basement membrane
for epithelial tissue formation.4-6 Hyaluronan is also a critical component of the developing heart and palatal shelf
matrix,7-9 alongside important roles in other specialized
tissues, including the vitreous humor of the eye10 and synovial ﬂuid of synovial joints.11 HYAL1 alterations are
associated with mucopolysaccharidosis type IX (OMIM
601492), which is characterized by short stature, craniofacial dysmorphism, submucosal cleft palate, and joint abnormalities.12 The potential parity between HYAL2 and
HYAL1 disruption supports the importance of maintained
hyaluronan modeling for normal craniofacial and palatal
shelf development. In this study, we describe the clinical,
genetic, and molecular ﬁndings associated with putative
HYAL2 pathogenic variants in 10 individuals from 6 families of Amish, Romanian, Italian, and North European
ancestry.

Materials and Methods
Patient ascertainment and genetic studies
Affected individuals were identiﬁed by their clinician and
using GeneMatcher (Baylor-Hopkins Center for Mendelian
Genomics - https://genematcher.org, accessed June 15,
2021). Phenotypic information was obtained by the clinical
care provider using a targeted questionnaire with informed
consent. DNA was extracted from blood/buccal samples
using standard techniques for exome/genome sequencing.
Variants with <5 reads, a frequency of >1% in the Genome
Aggregation Database (gnomAD, Broad Institute) v2.1.1
and/or in-house databases were excluded. Exonic or intron/
exon boundary (±6 nucleotides of the splice junction) de
novo, homozygous, or compound heterozygous variants
were evaluated and prioritized by call quality, allele frequency (minor allele frequency), inheritance pattern, and
predicted functional consequence as previously described at
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Baylor College of Medicine (Individual 2; research trio
exome sequencing),13 Ospedale Pediatrico Bambino Gesù
(Individual 3; research trio exome sequencing),14-16 Children’s Mercy Kansas (Individual 4; research trio genome
sequencing),17 GeneDx (Individual 6; diagnostic exome),18
Children’s Hospital of Philadelphia (Individual 7; research
trio exome sequencing),19 and through the 100,000 Genomes Project (Individual 8; research trio genome
sequencing, with gene-agnostic variant ﬁltering) (see
Supplemental text).20 Cosegregation studies were undertaken using dideoxy DNA sequencing (Supplemental
Figures 1 and 2). HYAL2 variants were deposited in ClinVar (SCV001572828-SCV001572838). For additional details about variant ﬁltering methodologies, see Supplemental
Data.

Structural analyses
X-ray diffraction or nuclear magnetic resonance–derived
structures of human HYAL2 (Q12891) were sought in
UniProt and the Protein Data Bank to identify the 3dimensional geometry and protein/substrate interactions
of HYAL2 pathogenic missense variants, but no structures
were found. Consequently, HYAL2 homologues were
sought using the Basic Local Alignment Search ToolProtein to identify a human HYAL1 (Q12794) structure
(2PE4) with 43% sequence identity, including complete
concordance in all HYAL2 putative pathogenic missense
residues and >50% identity in a region surrounding the
clustered missense variants (amino acids 130-280)
(Supplemental Figure 3). A homology model (https://
swissmodel.expasy.org/, accessed June 18, 2021) was
visualized and annotated using Pymol 2.3 (Schrödinger
LLC, 2019). Seven residues, previously shown to be
critical for HYAL1 catalytic function, and identical in
HYAL2, were annotated onto this model to highlight the
probable enzymatic active site.21 We then modeled each
HYAL2 amino acid substitution individually (FoldX5) to
identify local predicted conformational changes that might
perturb protein folding.22 Residues of interest were
examined using PhosphoSitePlus (www.phosphosite.org,
accessed June 15, 2021) to identify post-translational
modiﬁcations.
The 8 putative pathogenic missense variants appeared
clustered in 3-dimensional space (Supplemental Figure 4A)
around the active site of HYAL1 (Supplemental Figure 4B).
To quantify this, the mean (Euclidean) distance between
amino acid substitutions was calculated using the spatial.distance function (SciPy, Python 3). The mean Euclidean
distance for this cluster of 8 variants was the mean of each
pairwise comparison. A comparative distribution was
derived by calculating the mean Euclidean distance of 8
randomly selected residues from the same model over
20,000 iterations (Supplemental Figure 4C).
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Plasmid recombinant constructs for variant
functional studies
Putative pathogenic HYAL2 variants (NM_003773.4:
c.713T>G, c.611G>C, c.1271_1272delAC, c.194C>G,
c.1273T>G, c.829C>T, c.883C>T) were introduced into
the HYAL2 complementary DNA expression vector
pCMV6-XL5 by fusion polymerase chain reaction (PCR) to
construct chimeric clones. Complementary primers specifying single-nucleotide variant substitutions or a deletion
(Supplemental Table 1) were used in combination with outer
primers (5′-atgcgggcaggcccaggccccacc-3′, forward; 5′gctacaaggtccaggtaaaggcca-3, reverse) to generate HYAL2
variants using Phusion High-Fidelity DNA Polymerase
(New England BioLabs). PCR fragments were gel-puriﬁed
and used as a PCR template using the outer primers for
restriction digestion, and pCMV6-XL5 vector used for gelpuriﬁcation, ligation, and transformation into electrocompetent DH5α E. coli.23 Positive clones were cultured
and plasmids were extracted and veriﬁed (dideoxy
sequencing) at the Toronto Centre for Applied Genomics. A
wild-type (WT) HYAL2 vector with a 5′ deletion that does
not express HYAL2 comprised the negative control.

Human HYAL2 expression analysis
HYAL2 transient expression (4.0 μg plasmid) was performed
in Hyal2–/– mouse embryonic ﬁbroblasts using TurboFect
reagent (Thermo Fisher Scientiﬁc) in 6-well plates followed
by immunoblot, immunoﬂuorescence, or phosphoinositolphospholipase C (PI-PLC) analysis. For immunoblotting,
cells were collected 48 hours after transfection, washed with
cold phosphate-buffered saline (PBS), and lysed (sonication). HYAL2 was detected by immunoblotting with rabbit
anti-HYAL2 antibody (Proteintech AP-15115) and antirabbit horseradish peroxidase secondary antibody. Signals
generated (Immobilon Western Chemiluminescence Kit,
Millipore) were detected on a ChemiDoc imager (Bio-Rad
Laboratories) with equal loading veriﬁcation (β-actin).
For immunoﬂuorescence, transfected cells were replated
onto coverslips at 24 hours with HYAL2 detected in permeabilized and/or processed unpermeabilized cells (48
hours). Cells were washed (PBS), incubated (1% bovine
serum albumin/PBS, 1 hour), and labeled (rabbit polyclonal
anti-HYAL2 antibody, 1:250, 15115-1-AP; ProteinTech) for
2 hours at room temperature before detection (Alexa Fluor
568-conjugated donkey anti-rabbit secondary antibody,
1:500, A10042; Life Technologies) and Hoechst dye 33342
staining and imaging (Axio Imager.Z2, 63×/1.4NA oil
objective).
To detect glycosylphosphatidylinositol (GPI)-anchored
cell surface hHYAL2 at 48 hours after transfection, the
entire population of cells in a transfected conﬂuent well of a
6-well plate was washed (PBS ×2) and incubated (37 ◦ C, 2
hours) with 0.5 U/mL PI-PLC (Sigma-Aldrich, P-5542)
in serum-free Dulbecco’s Modiﬁed Eagle Medium
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supplemented with 25 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid pH 7.4 (0.5 mL/well with
gentle rocking). The medium from each well was collected
and concentrated (Biomax 0.5 mL spin concentrators) for
use as single samples. Sample proteins were separated
(sodium dodecyl sulfate–polyacrylamide gel electrophoresis) and PI-PLC released cell surface HYAL2 was
detected by immunoblotting.

Results
Clinical and genetic ﬁndings
Table 1 summarizes the core phenotypic features of 10
individuals (2 Amish) aged 0 to 20 years with HYAL2
deﬁciency syndrome, alongside 7 individuals from Muggenthaler et al1 shown for comparison (Supplemental
Table 2) (full clinical synopsis for each proband/family
provided in Supplemental Data). Affected individuals share
distinctive craniofacial similarities, including frontal bossing, hypertelorism, a broad and ﬂattened nasal tip, and
cupped ears with superior helices (Figure 1). Other common
but variable clinical features included cleft lip and palate
(both unilateral and bilateral); congenital cardiac anomalies,
including valvular, atrial/ventricular septal defects; ocular
features, including mild to severe myopia and cataracts;
single palmar crease; and pectus excavatum.
In each newly reported affected individual, genomic
studies (see Supplemental Data for description) identiﬁed
pathogenic or likely pathogenic homozygous or compound
heterozygous HYAL2 variants as a likely cause of disease (for
full American College of Medical Genetics and Genomics/
Association of Molecular Pathology classiﬁcations refer
to Supplemental Table 3). In Individuals 1 and 2, the
pathogenic Amish HYAL2 founder variant (Chr3
[GRCh38]:g.50320047T>C, NM_003773.4:c.443A>G; p.
[Lys148Arg]), deﬁned in our previous studies1 and with an
allele frequency of 0.6% in the Anabaptist variant server
comprising >10,000 exomes, was identiﬁed (Supplemental
Figure 1). The homozygous Amish founder MTPAP variant
(Chr10[GRCh38]:g.30313926T>C, NM_018109.3:c.1432
A>G; p.[Asn478Asp]), marked as pathogenic by ClinVar
(VCV000018391.1) and known to cause mild-moderate
developmental delay, optic atrophy, and spastic ataxia, was
also identiﬁed in Individual 2, likely explaining these
phenotypic features.24 Compound heterozygous novel pathogenic missense and nonsense HYAL2 variants were identiﬁed in Individual 3 (Chr3[GRCh38]:g.50319661G>A,
NM_003773.4:c.829C>T; p.[Arg277Cys], Chr3[GRCh
38]:g.50319607G>A, NM_003773.4:c.883C>T; p.[Arg
295*]). In siblings, Individuals 4 and 5, compound heterozygous pathogenic nonsense and missense HYAL2 variants
were identiﬁed (Chr3[GRCh38]:g.50320296G>C, NM_
003773.4:c.194C>G; p.[Ser65*] Chr3[GRCh38]:g.503
18278A>C, NM_003773.4:c.1273T>G; p.[Phe425Val]).

Genotype

p.(Lys148Arg) |
p.(Lys148Arg)
Amish, F, 13.8 y

p.(Lys148Arg) |
p.(Lys148Arg)
Amish, M, 9.4 y

3

4
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Table 1 Clinical features of affected individuals with HYAL2 deﬁciency
Individual
1
2

5

p.(Arg277Cys) |
p.(Arg295*)
Italian, M, 19 y

p.(Ser65*) |
p.(Ser65*) | p.(Phe425Val)
p.(Phe425Val)
North European, F,
North European, M, died 10 d
Ethnicity, Sex, Agea
died 10 mo
152.5 (–0.93)
124.5 (–1.83)
163.5 (–1.75)
53 (+1.42)
51 (+0.23)
Height, cm (SDS)b
OFC, cm (SDS)b
55.5 (+0.51)
54.2 (–0.07)
53.7 (+0.51)
33.5 (–1.32)
35.5 (+0.23)
Broad nasal bridge
✓
✓
✓
✓
✓
Hypertelorism
✓
✓
✓
✓
✓
External ear abnormalities ✓ Small, overfolded
✓ Small, overfolded
✓ Small, overfolded
✓ Small, low set,
✓ Low set, cupped, thick
thickened helices
thickened helices
thickened helices
small lobule, R ear pit
helix, prominent tragus
Cleft lip/palate
✖
✖
✖
✓ R CLP
✓ R CLP
Micrognathia
✓
✓
✖
✓
✓
Frontal bossing
✓
✓
✖
✖
✓
Ptosis
✖
✖
✓
✖
✓
Cardiac anomalies
✓ Mild AS and AR
✖
✓ CoA and VSD
✓ VSD, ASD, PDA, PHTN
✓ Complex
Pectus excavatum
✖
✓
✓
✖
✖
Single palmar crease
✓
✓
✖
✖
✓
Myopia (refraction)
✓ Mild
NK
✓ Severe
✓ Mild
NK
Cataract
✖
✖
✓ Bilat.
NK
NK
Other ocular features
Poor vision
Myopic maculopathy, RD
PPM R VH
Hearing loss
✖
✖
✖
✖
✓Failed NBHS on L side
Duodenal web
NK
NK
NK
✓
NK
Broad deviated thumbs,
Other clinical ﬁndings
Broad halluces, broad Ataxia, mild/moderate developmental delay, Accessory oral frenulum
Cystic hygroma at 11 wk,
hypoplastic nails, prominent
broad halluces broad thumbs
low posterior hairline
and distally
hydrops, hypoplastic
creases, bilat. extrarenal
Short, webbed neck
placed thumbs
nails, small penis, bilateral
pelvises, congenital
undescended testicles,
large anterior fontanelle
diaphragmatic hernia,
glabellar capillary nevus,
cystic hygroma
Comorbid diagnosis
Spastic ataxia 4,
autosomal recessive
(continued)

J. Fasham et al.

Genotype
Ethnicity, Sex, Agea
Height, cm (SDS)b
OFC, cm (SDS)b
Broad nasal bridge
Hypertelorism
External ear abnormalities
Cleft lip/palate
Micrognathia
Frontal bossing
Ptosis
Cardiac anomalies
Pectus excavatum
Single palmar crease
Myopia (refraction)
Cataract
Other ocular features
Hearing loss
Duodenal web
Other clinical ﬁndings

Comorbid diagnosis

6

7

8

9

10

Summaryc

p.(Gly204Ala)|
p.(Gly204Ala)
Turkish, F, 20y
151 (–2.09)
51 (–3.26)
✓
✓
✓ Small ear lobes,
chronic otitis media
✓ Bilat. CLP
✖
✖
✖
✖
✓
✖
✓ High
✖
L RD with enucleation
R macular atropy
✓ R: mild-sev. SNHL
L: mild-profound mixed
NK
Intellectual disability,
No speech until 3 y,
autism spectrum
disorder, ADHD,
ﬁngertip whorls,
ﬁnger webbing,
webbed neck
Retinitis pigmentosa 2

p.(His424Leufs*12) |
p.(Leu238Arg)
German, M, 4 y
NK
NK
✓
✓
✓ Small, overfolded, thick
helix, low set, small lobule
✓ R CLP
✖
✖
✖
✓ ToF
✖
✓
✓ High
✖
Myopic maculopathy,
rod dystrophy suspected
✖

p.(Arg378Cys)|
p.(Ala64Thr)
Polish, F, 8.6 y
129.9 (–0.14)
50.7 (–0.83)
✓
✓
✖

p.(Arg378Cys)|
p.(Ala64Thr)
Polish, M, ToP
NK
NK
NK
NK
NK

p.(Arg378Cys)|
p.(Ala64Thr)
Polish, M, 4.3 y
93.7 (1.12)
47 (–1.35)
✓
✓
✓ L preauricular pit

-

✖
✖
✖
✖
✓ ToF
✖
✖
✓ High
✖

Not reported
NK
NK
NK
✓ Hypoplastic left heart
NK
NK
NK
NK
NK

✖
✖
✖
✖
✓ DORV, VSD
✖
✓
Suspected
✖

10/17
9/14
5/14
5/13
12/17
7/16
9/13
11/11
2/8
-

✖

NK

✖

7/16

NK
Broad halluces
Cryptorchidism
Short neck ﬁfth
ﬁnger clinodactyly

✖
Broad thumbs

NK
NK

✖
Bilateral 2-3 toe
syndactyly

2
-

(Median: –0.93)
(Median: –1.32)
13/14
13/16
11/14
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Table 1 Continued
Individual

(✓) and (✖) indicate presence and absence of a feature in an affected subject, respectively.
ADHD, attention deﬁcit hyperactivity disorder; AR, aortic regurgitation; AS, aortic stenosis; ASD, atrial septal defect; AV, aortic valve, Bilat., bilateral; BMI, body mass index; CoA, coarctation of aorta; CLP, cleft
lip and palate; D, dioptres; DORV, double outlet right ventricle; F, female; L, left; M, male; NBHS, newborn hearing screen; NK, not known; OFC, occipitofrontal circumference; PDA, patent ductus arteriosus; PHTN,
pulmonary hypertension; PPM, persistent pupillary membrane; R, right; RD, retinal detachment; SDS, SD score; sev., severe; SNHL, sensorineural hearing loss; ToF, tetralogy of Fallot; ToP, termination of pregnancy;
Unilat, unilateral; VH, vitreous hemorrhage; VSD, ventricular septal defect.
a
Refers to decimal age of examination.
b
Height, weight, BMI, and OFC Z-scores were calculated using a Microsoft Excel add-in to access growth references based on the LMS (Lambda Mu Sigma) method using a reference European population (https://
www.healthforallchildren.com/, accessed September 3, 2021).
c
Including 7 individuals from Muggenthaler et al1 (Supplemental Table 2).
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Figure 1 Facial features of individuals with HYAL2 deﬁciency, with new clinical photographs of individuals from Muggenthaler
et al1 for comparison. Key features include frontal bossing, hypertelorism, a broad and ﬂattened nasal tip, and cupped ears with overfolding
of the superior helices. A, F. Individual XII:7 from Muggenthaler et al,1 (our Supplemental Figure 1 pedigree reference X:1). B, G. Individual
XII:9 from Muggenthaler et al1 (our Supplemental Figure 1 pedigree reference X:3). C, H. Individual 6. D, I. Individual 8. E, J. Individual 10.
K, L. Individual 3. M. Individual 4. N. Individual 5. O. Individual 7.

The nonsense variant is located in exon 2/4 with the resulting
transcript expected to undergo nonsense-mediated decay. In
Individual 6, a likely pathogenic homozygous HYAL2
missense variant (Chr3[GRCh38]:g.50319879C>G; NM_
003773.4:c.611G>C; p.[Gly204Ala]) was identiﬁed alongside a homozygous RP2 missense variant (ChrX
[GRCh38]:g.46837108G>C, NM_006915.2:c.8G>C; p.[Cy
s3Ser]), reported as likely pathogenic by ClinVar (accession;
VCV000418458.2), potentially explaining the severity of this
individual’s ocular phenotype.25 In Individual 7, compound
heterozygous pathogenic frameshift and likely pathogenic
missense HYAL2 variants were identiﬁed (Chr3
[GRCh38]:g.50318279_50318280delGT, NM_003773.4:
c.1271_1272delAC; p.[His424Leufs*12], Chr3[GRCh
38]:g.50319777A>C, NM_003773.4:c.713T>G; p.[Leu23
8Arg]). The frameshift alteration is predicted to cause a premature stop codon in the ﬁnal exon (4/4) and escape
nonsense-mediated decay, producing a truncated protein
(436/473 amino acids). In Individuals 8, 9, and 10, two likely
pathogenic missense HYAL2 variants in trans were identiﬁed
(Chr3[GRCh38]:g.50318419G>A, NM_003773.4:c.1132C

>T; p.[Arg378Cys], and Chr3[GRCh38]:g.50320300C>T,
NM_003773.4:c.190G>A; p.[Ala64Thr]).
All variants cosegregated as expected for an autosomal
recessive disorder (Supplemental Figures 1 and 2) and were
absent or rare in gnomAD (allele frequency <0.0001,
Supplemental Table 4). All missense alterations affected
evolutionarily conserved amino acid residues (Supplemental
Figure 5) and were predicted deleterious (Supplemental
Table 4).

Expression of HYAL2 variants
HYAL2 gene variants identiﬁed in Individuals 3 to 7 were
introduced into human HYAL2 complementary DNA to
assess the impact on HYAL2 levels after transient expression in Hyal2–/– mouse embryonic ﬁbroblasts, with functional studies of p.(Lys148Arg) and p.(Pro250Leu) having
been performed in previous work.1 Protein levels were
compared with WT HYAL2 by transient transfection and
immunoblot analysis. The Ser65* and Arg295* premature
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terminations resulted in no detectable HYAL2 protein,
whereas the Leu238Arg, Phe425Val, and Arg277Cys alterations displayed very low protein levels, suggesting
accelerated degradation (Figure 2A). Two variants,
Gly204Ala and His424Leufs*12, were present at levels
similar to WT protein (Figure 2B). The His424Leufs*12
variant resulted in 2 prominent forms of HYAL2
(Figure 2A), which when treated with PNGase F to remove
N-linked glycans, resulted in a single protein band that was,
as expected, smaller in size than the band from similarly
treated WT HYAL2 (Supplemental Figure 6A).

Impact of HYAL2 variants on HYAL2 localization
Proper HYAL2 processing includes modiﬁcation by introduction of a GPI anchor for cell surface localization. Variants impacting protein folding may lead to endoplasmic
reticulum (ER)-mediated degradation and/or a failure in Cterminal GPI anchor addition; such variants would be expected to reduce cell surface HYAL2 levels. To explore this
hypothesis, we performed immunoﬂuorescence studies using transfected cells under nonpermeabilized conditions
(cell surface HYAL2) and permeabilized conditions (intracellular HYAL2) and analyzed HYAL2 released from the
surface with phospholipase C (PLC) (Figure 2C). WT
HYAL2 was abundantly detected at the cell surface and
within cells using immunoﬂuorescence (Figure 3). Importantly, no variant resulted in cell surface HYAL2 levels that
were comparable with the levels in WT, although several
variants enabled substantial expression of intracellular
HYAL2. No intracellular or cell surface HYAL2 was
detected for termination codons (p.[Ser65*] and
p.[Arg295*]). Low levels of cell surface expression could be
detected for p.(Leu238Arg) and p.(Gly204Ala).

Removal of cell surface HYAL2 with PLC
To conﬁrm the low levels of cell surface HYAL2 in cells
expressing mutant HYAL2 constructs, we released cell surface HYAL2 with PI-PLC (Figure 2C). Media collected
from cells expressing WT HYAL2 were analyzed before
and after treatment with PI-PLC. A low level of HYAL2
(–PLC) was detected in the medium, but this was much
lower than the amount released after 2 hours of incubation
with PI-PLC. The large number of cells used in this
experiment allowed the clear conﬁrmation of cell surface
mutant HYAL2 that was only faintly apparent by immunoﬂuorescence. Only 2 variants, Leu238Arg and
Gly204Ala, led to substantial HYAL2 levels released from
the cell surface, consistent with immunolocalization results.
Interestingly, although WT HYAL2 has 2 forms that can be
detected by immunoblot, 1 band predominated in the presence of each HYAL2 variant. PNGaseF treatment of these
samples showed that these 2 bands differ only in glycosylation (Supplemental Figure 6B), suggesting that the variants
differently impact folding and glycosylation rates in the ER.
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HYAL2 variant structural homology modeling
In total, 7 of 8 missense HYAL2 variants affect residues
located internally away from the HYAL2 molecular surface,
making it unlikely that they directly bind ligands
(Figure 2D). In all but 1 case (Ala64Thr), in silico analysis
predicted these variants destabilize protein folding
(Supplemental Table 5). In contrast, the only missense
variants within our model that were present in homozygous
state in gnomAD v2.1.1, Ile418Ser and Trp440Arg, were
found at the protein periphery with side chains projecting
outward and were either stabilizing or only very mildly
destabilizing to protein folding. The Lys148Arg variant
located on the protein surface is predicted to mildly
encourage the folded state. However, because Lys148 entails the only known HYAL2 ubiquitinated residue,26 it may
have a speciﬁc and key functional molecular role (eg, in
signaling).
As expected, structural modeling deﬁned a putative
substrate binding cleft and the key catalytic residues in the
same conformation as HYAL1 (Supplemental Figure 4A
and B). Pathogenic HYAL2 residues were all identical in
HYAL1 (Supplemental Figure 3), and notably, Lys148Arg
is located within the predicted binding cleft. In total, 7 of 8
pathogenic missense variants cluster in the region of the
substrate binding cleft (Supplemental Figure 4A and B),
which is further supported by analysis of variant mean
Euclidean distance in the lowest 3% (Z <–1.89) of all such
groupings of this size in this protein (Supplemental
Figure 4C).

Discussion
The clinical and genetic studies described herein establish
HYAL2 gene variants as a cause of syndromic cleft lip and/
or palate, and our molecular ﬁndings identify HYAL2
protein deﬁciency as the pathomolecular basis of disease.
The comprehensive comparison with our previously reported cases, initially elucidated as founder alleles, deﬁne
the core and variable clinical features that characterize the
condition.
A recognizable pattern of craniofacial dysmorphism
is invariably present, although a cleft lip and palate––previously
considered to be a core clinical feature––is now shown through
our larger cohort to be a common but more variable feature than
previously thought. Auricular anomalies (cupped ears, overfolded helices), previously identiﬁed in a minority of individuals, are now noted in more than half of individuals and
frontal bossing, a broad nasal tip, micrognathia, and pectus
excavatum (Supplemental Figure 7) are considered variable
features. Congenital cardiac anomalies, identiﬁed in most new
cases, comprise an important component of the disease
phenotype, and we identiﬁed a number of clinically signiﬁcant
anomalies likely to require surgical intervention in the ﬁrst year
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Figure 2 Functional studies and protein modeling of pathogenic HYAL2 variants reported to date. A. Expression of HYAL2 in
Hyal2–/– mouse embryonic ﬁbroblasts (MEFs). Immunoblot analysis of protein lysates (10 μg per lane) prepared from transfections with
HYAL2 expression vectors were analyzed with anti-HYAL2 (upper panel) and anti-β-actin (lower panel). HYAL2 is indicated by an arrow,
and the asterisk indicates a cross reacting band that is evident even in the control. A second band, resulting from N-linked glycosylation of
HYAL2, is apparent for His424Leufs*12. This band disappears after treatment with PNGase F (Supplemental Figure 6). The control was
transfected with a vector that does not express HYAL2. B. Quantiﬁcation of the immunoblots. The average ± SEM of the luminescence units
from 4 separate transfection experiments are shown by the bars. The signiﬁcance for each variant compared with the wild type (WT) was
determined using a paired t test using the ratios from each experiment. P ≤ .0001 (****); P ≤ .001 (***); P ≤ .01 (**). C. Immunoblot
analysis of HYAL2 released by phosphoinositol-phospholipase C (PI-PLC) treatment. Hyal2–/– MEFs that were transfected with WT HYAL2
and HYAL2 variants were incubated with (+) or without (–) phospholipase C to release the cell surface HYAL2. HYAL2 was detected by
immunoblot after the protein in the media was concentrated from the entire population of cells in a conﬂuent well of a 6-well plate. This blot
is representative of 3 independent experiments. Apparent difference in molecular weight between Gly204Ala and Leu238Arg result from
differential N-linked glycosylation (Supplemental Figure 6B). A shorter exposure image (Supplemental Figure 6C) conﬁrmed the highly
abundant WT (+) band to be singular. No quantiﬁcation was performed owing to the possibility of variability in PI-PLC efﬁciency
signiﬁcantly affecting these values. D. HYAL2 three-dimensional (3D) homology modeling using a crystal structure of HYAL1(2PE4)
showing the position of described variants. Pathogenic variants are highlighted in red; variants present in a homozygous state in gnomAD
v2.1.1 are colored yellow. E. The previously experimentally determined active site of HYAL1 shown on the same HYAL2 3D homology
model as shown in D. ns, not signiﬁcant.

of life (coarctation of the aorta, mitral valve atresia, hypoplastic
left ventricle, pulmonary valve atresia, and tetralogy of Fallot).
The presence of these severe phenotypes and the high overall
incidence of cardiac defects in the affected individuals underscore the importance of cardiac screening at birth with pulse
oximetry and echocardiography, allowing early detection of

defects that may require surgical intervention to reduce the risk
of morbidity and mortality associated with a delayed diagnosis27 (Supplemental Table 6).
Myopia, originally described in only 2 individuals in our
initial publication, is now conﬁrmed as another core clinical
feature, being present in all individuals examined. This may
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Figure 3 Comparative immunolocalization of Hyal2–/– mouse embryonic ﬁbroblasts (MEFs) expressing HYAL2 variants. The
transfected Hyal2–/– MEFs were ﬁxed and incubated with anti-HYAL2 primary antibody under non-perm and perm conditions. HYAL2 is
detected with Alexa Fluor 568-conjugated donkey anti-rabbit secondary antibody and is labeled with orange ﬂuorescence. Nuclei are stained
blue with Hoechst. Scale bars, 20 μm. 63× magniﬁcation. Representative microscopy images from at least 3 independent experiments are
shown. perm, permeabilized.

640
be particularly severe (up to –16.75 dioptres) and associated
with complications including myopic macular degeneration
(4 individuals) and retinal detachment (2 individuals). Individual 6 displayed a particularly severe phenotype with
high myopia leading to unilateral retinal detachment,
potentially caused by coinheritance of a homozygous RP2
variant previously described as pathogenic in a single
hemizygous male with retinitis pigmentosa (OMIM
312600)25 but also present in 3 hemizygous males in gnomAD v.2.1.1. Additional ocular ﬁndings in some individuals, including posterior subcapsular cataract and
wedge-shaped cortical cataract, suggest high myopia may
be part of a hereditary vitreoretinal degeneration phenotype.
The human vitreous is a specialized extracellular matrix
composed of hyaluronan, the major macromolecule, interwoven with chondroitin sulfate proteoglycans (including
versican and collagen IX) and other collagen ﬁbrils.10
Versican binds to hyaluronan via a hyaluronan-binding
domain located in the globular N-terminal region.28 Of
note, pathogenic variants in VCAN, encoding versican, are
associated with vitreoretinopathy, Wagner syndrome
(OMIM 143200), and are implicated in congenital cardiac
defects.29 These observations deﬁne HYAL2 as being critically important for ocular and cardiac development, with
decreased hyaluronan and/or chondroitin sulfate degradation
likely underlying ocular and cardiac disease in patients. In
view of the association with high myopia and associated
complications and the possible association with a more severe vitreoretinal degeneration phenotype, we suggest regular ophthalmic examinations from infancy to enable early
detection and treatment of ocular pathologies (see
Supplemental Table 6 for proposed clinical guidelines).
Hearing loss, noted in 5 of 7 of the originally described
individuals, was present in only 2 of 9 new cases, possibly
reﬂecting the reduced incidence of cleft palate, which is
commonly associated with conductive hearing loss. However, screening for hearing loss in all patients at diagnosis is
recommended because we cannot exclude an independent
association with HYAL2 deﬁciency (Supplemental
Table 6). Two affected individuals (2 and 6) in our study
were considered to have cognitive impairment, although for
individual 2 an explanatory second diagnosis was identiﬁed
(MTPAP-related spastic ataxia). Individual 6 is also
microcephalic, and it remains unclear whether these aspects
of her condition are caused by a comorbid disorder.
Importantly, for most patients, cognitive ability is unaffected, information that will aid genetic counseling for this
condition (Supplemental Table 6).
This study also identiﬁed the ﬁrst 3 individuals with a
loss-of-function HYAL2 variant in trans with a missense
HYAL2 variant (Individuals 3, 4, and 5) who notably
exhibited cardiac anomalies at the more severe end of the
spectrum (coarctation of the aorta, mitral valve atresia),
with 1 also having severe myopia. These ﬁndings may
indicate an emerging genotype–phenotype relationship
regarding protein functionality and cardiac/ocular
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phenotype severity, which may ultimately aid reﬁnement
of clinical screening and enable the interpretation of
missense alterations beyond variant of unknown
signiﬁcance.
HYAL2 is a cell-surface protein that undergoes complex
cotranslational modiﬁcation before achieving its ﬁnal topology as a mature GPI-anchored cell surface glycoprotein.
The c-translational steps required to generate mature
HYAL2 begin in the ER, where, like other glycoproteins,
even apparently conservative amino acid substitutions may
lead to ER-associated degradation and HYAL2 deﬁciency.
Our functional assays determined that the nonsense variants
Ser65* and Arg295* lead to no detectable intracellular or
cell surface HYAL2 protein (Figure 2 and 3). Although
these shorter peptides are likely unstable in this transient
overexpression system, in the endogenous situation the
transcripts would likely be subjected to nonsense-mediated
messenger RNA decay, leading to no HYAL2 protein. Our
studies also revealed that Phe425Val, Leu238Arg, and
Arg277Cys substitutions also result in low total levels of
HYAL2, indicating mutant protein instability (Figure 2).
Interestingly, expression levels of Gly204Ala and
His424Leufs*12 mutant proteins remain similar to WT
levels (Figure 2). As the His424Leufs*12 entails a 2 base
pair deletion within the ﬁnal exon of HYAL2, this is not
unexpected given such last exonic alterations may escape
nonsense-mediated decay and generate truncated albeit
stable mutant protein products.30,31 Immunoﬂuorescence
and PI-PLC studies show that although some variants
permit intracellular expression of mutant HYAL2, all
impact HYAL2 levels at the cell surface, with reduced
(Gly204Ala and Leu238Arg) or absent (Phe425Val,
Arg277Cys, and His424Leufs*12) levels of mature HYAL2
detected or released at the cell surface (Figure 2 and 3).
Also of note, while Leu238Arg is depleted intracellularly, it
displays notable expression at the cell surface, although far
below WT levels and similar to Gly204Ala. Interestingly,
the Leu238Arg mutant protein has increased N-linked
glycosylation, suggesting it has prolonged ER retention,
possibly leading to a transient localization to the cell surface
en route to the lysosome.32 Taken together, these ﬁndings
show that all putative pathogenic variants assessed to date
affect HYAL2 stability and/or HYAL2 functional
deﬁciency.
Our homology models support these functional studies,
suggesting that 6 of the 8 identiﬁed missense variants impact
buried residues, which would be strongly deleterious to
folding and likely lead to removal of mutant protein
(Supplemental Table 5). Of these, Gly204Ala had the
smallest predicted deleterious effect, consistent with our
ﬁndings of normal protein expression levels and reduced
(but not abolished) cell surface expression. One pathogenic
variant, Lys148Arg, which was previously shown to reduce
protein expression,1 was not predicted by homology
modeling to be deleterious to folding. This residue represents the only HYAL2 ubiquitination site,26 marking the
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protein for degradation and trafﬁcking; this likely explains
the apparent deleterious nature of this variant. Furthermore,
the altered side chain of the Lys148Arg substitution projects
directly into the putative binding cleft and leads to altered
hydrogen bonding (Figure 2D). In silico modeling also
identiﬁed a clustering of 7 of the 8 missense variants near to
the putative binding cleft, whereas variants present in the
homozygous state in gnomAD were clustered at the periphery with side chains projecting outward. The importance
of this clustering remains unclear because the protein levels
are low in affected individuals.
HYAL2 is broadly expressed both in mouse and human
tissues, and the signiﬁcant parity in mouse and human phenotypes associated with HYAL2 deﬁciency has permitted
new insights into the mechanistic basis of developmental
defects in HYAL2-related disease. Despite the controversy
surrounding the precise role of HYAL2 in hyaluronan turnover,33,34 tissues from mice deﬁcient in HYAL2 show substantial accumulation of hyaluronan, indicating that HYAL2
is clearly involved in hyaluronan removal from the extracellular matrix.35 Studies have also shown that a failure
to remove hyaluronan leads to increased epithelial-tomesenchymal transition (EMT) and decreased differentiation.36 We hypothesize that this mechanism underlies the
cardiac anomalies observed in mice and humans with HYAL2
deﬁciency. During cardiac development, EMT within cardiac
cushions establishes the primordium that develops into cardiac valves and the ventricular septum.37 Removal of high
molecular mass hyaluronan from the provisional extracellular
matrix is shown to be critical to heart development38,39 such
that increased hyaluronan in the absence of HYAL2 would
lead to excess EMT and decreased differentiation affecting
cardiac development. In keeping with this, HYAL2-deﬁcient
mice show increased numbers of mesenchymal cells in the
heart and expanded cardiac valves and accessory tissues,38,39
and congenital cardiac defects are a major clinical feature of
HYAL2 deﬁciency in humans.
A similar mechanism may underlie the craniofacial
anomalies in HYAL2 deﬁciency. Overall, the craniofacial
appearance of individuals carrying pathogenic HYAL2 variants resembles the phenotypic spectrum of frontonasal
dysplasias, with overlapping features, including hypertelorism, nasal anomalies, and midline orofacial clefts.
These features can arise from defects in midline craniofacial
development, a process involving the fusion of 3 separate
facial processes through a combination of programmed cell
death and conversion of epithelial cells into mesenchyme
via EMT.40 Craniofacial bones of Hyal2–/– mice show a
central ossiﬁcation defect, suggesting decreased differentiation in Hyal2–/–embryonic tissues.1 This supports increased
hyaluronan accumulation, which leads to improperly regulated EMT, and decreased differentiation as a common
mechanistic pathway underlying some of the congenital
craniofacial and cardiac abnormalities seen in both humans
and mice deﬁcient in HYAL2.
Although Hyal2–/– knockout mice are viable (albeit with
signiﬁcant preweaning lethality and reduced survival),1 the
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absence of clear human knockouts in affected individuals
identiﬁed to date may indicate that HYAL2 plays a crucial
role in human growth and development, and its complete
absence may be incompatible with human life. Although the
speciﬁc developmental cascades impaired by HYAL2 deﬁciency remain to be identiﬁed, it is clear that HYAL2
function is important for cardiac and craniofacial development. Together, our genetic, functional, and structural
modeling studies expand the molecular spectrum associated
with pathogenic HYAL2 variants and provide new insight
into the likely disease mechanism and functional roles of
HYAL2. Our comprehensive phenotyping assessments
enable a clearer delineation of the core and variable
phenotypical features of HYAL2 deﬁciency to be characterized. On the basis of the features described earlier, we
have proposed a set of general guidelines to aid the clinical
workup of patients affected by HYAL2 deﬁciency
(Supplemental Table 6). The precise functions of HYAL2 in
human growth remain incompletely understood, and further
studies are important to elucidate the precise molecular and
developmental roles of this molecule in cardiac, ocular, and
craniofacial development.

Data Availability
The variants listed in this paper have been deposited in the
ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/)
with accessions SCV001572828 - SCV001572838.
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16. Kortüm F, Caputo V, Bauer CK, et al. Mutations in KCNH1and
ATP6V1B2 cause Zimmermann–Laband syndrome. Nat Genet.
2015;47(6):661–667. http://doi.org/10.1038/ng.3282.
17. Willig LK, Petrikin JE, Smith LD, et al. Whole-genome sequencing for
identiﬁcation of Mendelian disorders in critically ill infants: a retrospective
analysis of diagnostic and clinical ﬁndings. Lancet Respir Med.
2015;3(5):377–387. http://doi.org/10.1016/S2213-2600(15)00139-3.
18. Guillen Sacoto MJ, Tchasovnikarova IA, Torti E, et al. De novo variants in the ATPase module of MORC2 cause a neurodevelopmental
disorder with growth retardation and variable craniofacial dysmorphism. Am J Hum Genet. 2020;107(2):352–363. http://doi.org/10.
1016/j.ajhg.2020.06.013.
19. Li D, March ME, Gutierrez-Uzquiza A, et al. ARAF recurrent mutation
causes central conducting lymphatic anomaly treatable with a MEK
inhibitor. Nat Med. 2019;25(7):1116–1122. http://doi.org/10.1038/
s41591-019-0479-2.
20. Turnbull C, Scott RH, Thomas E, et al. The 100 000 Genomes Project:
bringing whole genome sequencing to the NHS. BMJ.
2018;361:k1687. Published correction appears in BMJ. 2018;361:
k1952. https://doi.org/10.1136/bmj.k1687
21. Zhang L, Bharadwaj AG, Casper A, Barkley J, Barycki JJ,
Simpson MA. Hyaluronidase activity of human Hyal1 requires active
site
acidic
and
tyrosine
residues.
J
Biol
Chem.
2009;284(14):9433–9442. http://doi.org/10.1074/jbc.M900210200.
22. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The
FoldX web server: an online force ﬁeld. Nucleic Acids Res. 2005;33(Web
Server issue):W382–W388. http://doi.org/10.1093/nar/gki387.
23. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol. 1983;166(4):557–580. http://doi.org/10.1016/s00222836(83)80284-8.
24. Crosby AH, Patel H, Chioza BA, et al. Defective mitochondrial mRNA
maturation is associated with spastic ataxia. Am J Hum Genet.
2010;87(5):655–660. http://doi.org/10.1016/j.ajhg.2010.09.013.
25. Jayasundera T, Branham KE, Othman M, et al. RP2 phenotype and
pathogenetic correlations in X-linked retinitis pigmentosa. Arch Ophthalmol. 2010;128(7):915–923. http://doi.org/10.1001/archophthalmol.
2010.122.
26. Udeshi ND, Svinkina T, Mertins P, et al. Reﬁned preparation and use
of anti-diglycine remnant (K-ε-GG) antibody enables routine quantiﬁcation of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics. 2013;12(3):825–831. http://doi.org/10.
1074/mcp.O112.027094.
27. Eckersley L, Sadler L, Parry E, Finucane K, Gentles TL. Timing of
diagnosis affects mortality in critical congenital heart disease. Arch Dis
Child. 2016;101(6):516–520. http://doi.org/10.1136/archdischild-2014307691.

644
28. Reardon A, Heinegård D, McLeod D, Sheehan JK, Bishop PN. The
large chondroitin sulphate proteoglycan versican in mammalian vitreous. Matrix Biol. 1998;17(5):325–333. http://doi.org/10.1016/s0945053x(98)90085-3.
29. Priest JR, Osoegawa K, Mohammed N, et al. De novo and rare variants
at multiple loci support the oligogenic origins of atrioventricular septal
heart defects. PLoS Genet. 2016;12(4):e1005963. http://doi.org/10.
1371/journal.pgen.1005963.
30. Kurosaki T, Maquat LE. Nonsense-mediated mRNA decay in humans
at a glance. J Cell Sci. 2016;129(3):461–467. http://doi.org/10.1242/
jcs.181008.
31. Satpute-Krishnan P, Ajinkya M, Bhat S, Itakura E, Hegde RS, Lippincott-Schwartz J. ER stress-induced clearance of misfolded
GPI-anchored proteins via the secretory pathway. Cell.
2014;158(3):522–533. http://doi.org/10.1016/j.cell.2014.06.026.
32. Coban-Akdemir Z, White JJ, Song X, et al. Identifying genes whose
mutant transcripts cause dominant disease traits by potential gain-offunction alleles. Am J Hum Genet. 2018;103(2):171–187. http://doi.
org/10.1016/j.ajhg.2018.06.009.
33. Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A,
Lerman MI, Miller AD. Candidate tumor suppressor HYAL2 is a
glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for
jaagsiekte sheep retrovirus, the envelope protein of which mediates
oncogenic transformation. Proc Natl Acad Sci U S A.
2001;98(8):4443–4448. http://doi.org/10.1073/pnas.071572898.
34. Vigdorovich V, Miller AD, Strong RK. Ability of hyaluronidase 2 to
degrade extracellular hyaluronan is not required for its function as a

J. Fasham et al.

35.

36.

37.

38.

39.

40.

receptor
for
jaagsiekte
sheep
retrovirus.
J
Virol.
2007;81(7):3124–3129. http://doi.org/10.1128/JVI.02177-06.
Chowdhury B, Hemming R, Faiyaz S, Triggs-Raine B. Hyaluronidase
2 (HYAL2) is expressed in endothelial cells, as well as some specialized epithelial cells, and is required for normal hyaluronan catabolism.
Histochem Cell Biol. 2016;145(1):53–66. http://doi.org/10.1007/
s00418-015-1373-8.
Rodgers LS, Lalani S, Hardy KM, et al. Depolymerized hyaluronan
induces vascular endothelial growth factor, a negative regulator of
developmental epithelial-to-mesenchymal transformation. Circ Res.
2006;99(6):583–589.
http://doi.org/10.1161/01.RES.0000242561.
95978.43.
Hinton RB, Yutzey KE. Heart valve structure and function in development and disease. Annu Rev Physiol. 2011;73:29–46. http://doi.org/
10.1146/annurev-physiol-012110-142145.
Chowdhury B, Xiang B, Liu M, Hemming R, Dolinsky VW, TriggsRaine B. Hyaluronidase 2 deﬁciency causes increased mesenchymal
cells, congenital heart defects, and heart failure. Circ Cardiovasc
Genet. 2017;10(1):e001598. http://doi.org/10.1161/CIRCGENETICS.
116.001598.
Chowdhury B, Xiang B, Muggenthaler M, Dolinsky VW, TriggsRaine B. Hyaluronidase 2 deﬁciency is a molecular cause of cor triatriatum sinister in mice. Int J Cardiol. 2016;209:281–283. http://doi.
org/10.1016/j.ijcard.2016.02.072.
Farlie PG, Baker NL, Yap P, Tan TY. Frontonasal dysplasia: towards an
understanding of molecular and developmental aetiology. Mol Syndromol. 2016;7(6):312–321. http://doi.org/10.1159/000450533.

